Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Omuro, A. M.P.
Right arrow Articles by Abrey, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omuro, A. M.P.
Right arrow Articles by Abrey, L. E.
Related Collections
Right arrow All Clinical trials
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrowRelated Article
NEUROLOGY 2005;64:69-74
© 2005 American Academy of Neurology

Chemoradiotherapy for primary CNS lymphoma

An intent-to-treat analysis with complete follow-up

Antonio M.P. Omuro, MD, Lisa M. DeAngelis, MD, Joachim Yahalom, MD and Lauren E. Abrey, MD

From Memorial Sloan-Kettering Cancer Center, New York, NY.

Address correspondence and reprint requests to Dr. Lauren E. Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: abreyl{at}mskcc.org

Objective: To assess the efficacy and safety of a preradiation chemotherapy regimen in patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes.

Methods: In this prospective phase II trial, patients with a new diagnosis of PCNSL received two cycles of intrathecal (12 mg) and IV (1 g/m2) methotrexate (MTX), thiotepa (30 mg/m2), and procarbazine (75 mg/m2), prior to whole-brain radiotherapy (RT).

Results: Seventeen patients were enrolled (ages 26 to 71, median 53). Median Karnofsky performance scale score was 70. After chemotherapy, 7 patients (41%) had a complete response (CR) and 7 (41%) a partial response (PR). After RT, 13 (76%) patients achieved a CR, 2 (12%) a PR, and 2 (12%) had disease progression. Relapse occurred in 7 (41%) patients; median disease-free survival was 18 months. Fifteen (88%) patients have died: 8 (47%) from PCNSL, 5 (29%) from neurotoxicity, and 2 (12%) from unknown causes. Median overall survival was 32 months. Two patients (12%) are alive and disease free at 12 years follow-up. Nephrotoxicity was a minor complication, but grades 3 and 4 myelosuppression were found in 5 (29%) patients.

Conclusions: This regimen resulted in an efficacy and toxicity profile comparable to other combined modality treatments, despite the relatively low dose of methotrexate. It may be a useful option in patients unable to tolerate higher doses. Procarbazine and thiotepa are potential candidates for incorporation into chemotherapy regimens aiming to decrease the incidence of neurotoxicity. First relapse and neurotoxicity within 2 years of diagnosis seem to be critical for predicting long-term outcomes.

Received April 23, 2004. Accepted in final form September 13, 2004.


Related Article

January 11 Highlights
Neurology 2005 64: 2-3. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann OncolHome page
H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., November 18, 2009; (2009) mdp529v2.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al.
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist, May 1, 2009; 14(5): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol, January 1, 2009; 11(5): 503 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
J Vicuna-Kojchen, S Frenkel, T Siegal, E Shalom, I Chowers, and J Pe'er
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
Br J Ophthalmol, February 1, 2008; 92(2): 231 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt
Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma
Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
L. M. DeAngelis and F. M. Iwamoto
An Update on Therapy of Primary Central Nervous System Lymphoma
Hematology, January 1, 2006; 2006(1): 311 - 316.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.